Sutro Biopharma Inc. (STRO) and OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Comparing side by side

Since Sutro Biopharma Inc. (NASDAQ:STRO) and OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 38.42M 6.96 35.32M -2.21 0.00
OncoMed Pharmaceuticals Inc. 44.42M 0.84 8.10M 0.13 6.31

Table 1 showcases the gross revenue, earnings per share and valuation of Sutro Biopharma Inc. and OncoMed Pharmaceuticals Inc.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. -91.93% 0% 0%
OncoMed Pharmaceuticals Inc. -18.24% 25.8% 6.5%


Sutro Biopharma Inc. has a Current Ratio of 3.5 and a Quick Ratio of 3.5. Competitively, OncoMed Pharmaceuticals Inc.’s Current Ratio is 3.4 and has 3.4 Quick Ratio. Sutro Biopharma Inc.’s better ability to pay short and long-term obligations than OncoMed Pharmaceuticals Inc.

Analyst Ratings

In next table is given Sutro Biopharma Inc. and OncoMed Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sutro Biopharma Inc. 0 0 0 0.00
OncoMed Pharmaceuticals Inc. 0 1 0 2.00

Competitively the average target price of OncoMed Pharmaceuticals Inc. is $1.5, which is potential 56.32% upside.

Insider & Institutional Ownership

The shares of both Sutro Biopharma Inc. and OncoMed Pharmaceuticals Inc. are owned by institutional investors at 75.3% and 61% respectively. Sutro Biopharma Inc.’s share held by insiders are 8.5%. Competitively, insiders own roughly 0.7% of OncoMed Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%
OncoMed Pharmaceuticals Inc. -3.83% 7.72% -34.35% -65.67% -66.23% 9.81%

For the past year Sutro Biopharma Inc.’s stock price has smaller growth than OncoMed Pharmaceuticals Inc.


OncoMed Pharmaceuticals Inc. beats Sutro Biopharma Inc. on 10 of the 12 factors.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.